SNDX

Syndax Pharmaceuticals Inc

Sep 16 • 09:38AM ET

15.82

-0.02 -0.15 %

Healthcare • Biotechnology • USA • NASD

Peers: LLY MRK PFE JNJ BMY AMGN GILD REGN VRTX BMRN

| Held by: VTI IWM XBI VXF IWO IBB VTWO SCHA VHT LABU

Index	RUT	P/E	-	EPS (ttm)	-3.90	Insider Own	3.27%	Shs Outstand	86.06M	Perf Week	-0.72%
Market Cap	1.36B	Forward P/E	-	EPS next Y	-1.74	Insider Trans	-6.54%	Shs Float	83.33M	Perf Month	0.48%
Enterprise Value	1.25B	PEG	-	EPS next Q	-0.72	Inst Own	119.78%	Short Float	25.10%	Perf Quarter	58.32%
Income	-334.99M	P/S	17.43	EPS this Y	14.81%	Inst Trans	6.41%	Short Ratio	9.26	Perf Half Y	21.29%
Sales	78.18M	P/B	8.65	EPS next Y	45.21%	ROA	-62.43%	Short Interest	20.92M	Perf YTD	19.64%
Book/sh	1.83	P/C	2.99	EPS next 5Y	71.20%	ROE	-113.22%	52W High	22.50 -29.71%	Perf Year	-12.08%
Cash/sh	5.28	P/FCF	-	EPS past 3/5Y	- -15.16%	ROIC	-69.33%	52W Low	8.58 84.34%	Perf 3Y	-35.63%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-44.66% 73.25%	Gross Margin	96.17%	Volatility	4.99% 4.99%	Perf 5Y	-0.78%
Dividend TTM	-	EV/Sales	16.02	EPS Y/Y TTM	-15.38%	Oper. Margin	-433.37%	ATR (14)	0.74	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	4.55	Sales Y/Y TTM	2133.71%	Profit Margin	-428.48%	RSI (14)	57.21	Recom	1.08
Dividend Gr. 3/5Y	- -	Current Ratio	4.71	EPS Q/Q	-4.26%	SMA20	-1.36%	Beta	0.69	Target Price	37.50
Payout	-	Debt/Eq	2.19	Sales Q/Q	984.51%	SMA50	21.38%	Rel Volume	0.27	Prev Close	15.84
Employees	270	LT Debt/Eq	2.07	Earnings	Aug 04 AMC	SMA200	23.27%	Avg Volume	2.26M	Price	15.82
IPO	Mar 03, 2016	Option/Short	Yes / Yes	EPS/Sales Surpr.	18.32% 41.65%	Trades		Volume	42,907	Change	-0.15%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-10-25	Resumed	Stifel	Buy	$44
Sep-04-25	Resumed	Guggenheim	Buy	$34
Aug-05-25	Reiterated	BTIG Research	Buy	$43 → $56
Jul-10-25	Initiated	Goldman	Buy	$18
Oct-24-24	Initiated	UBS	Buy	$37
Jun-28-24	Initiated	Jefferies	Buy	$37
Jan-31-24	Downgrade	Scotiabank	Sector Outperform → Sector Perform	$36 → $23
Dec-22-23	Initiated	Mizuho	Buy	$45
Oct-25-23	Initiated	BofA Securities	Buy	$29
Oct-11-23	Initiated	Goldman	Buy	$30
Jul-27-23	Initiated	Scotiabank	Sector Outperform
Jul-11-23	Initiated	Guggenheim	Buy	$40
Apr-17-23	Resumed	BTIG Research	Buy	$34
Jan-31-23	Initiated	Stifel	Buy	$37
Jan-03-23	Initiated	JP Morgan	Overweight	$41
Jul-28-22	Resumed	B. Riley Securities	Buy	$31
Apr-11-22	Initiated	H.C. Wainwright	Buy	$31
Feb-15-22	Initiated	Goldman	Buy	$37
Jun-04-21	Resumed	Robert W. Baird	Outperform	$30 → $31
May-25-21	Initiated	Citigroup	Buy	$24

Show Previous Ratings

Sep-10-25 09:51AM	Synopsys downgraded, Oracle upgraded: Wall Street's top analyst calls (The Fly)
Sep-05-25 04:01PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) +5.25%
Sep-01-25 09:55AM	Wall Street Analysts Believe Syndax (SNDX) Could Rally 112.8%: Here's is How to Trade (Zacks)
Aug-28-25 01:59PM	Agilent Q3 Earnings Beat Estimates, Revenues Up Y/Y, Shares Rise (Zacks)
Aug-26-25 07:00AM	Syndax Announces Participation in September Investor Conferences (GlobeNewswire)
11:42PM	Loading…
Aug-18-25 11:42PM	Regulatory Milestone and Analyst Optimism Fuel Momentum for Syndax Pharmaceuticals (Insider Monkey)
Aug-17-25 11:41PM	BTIG Raises Syndax Pharmaceuticals (SNDX) PT to $56 Following Strong Q2 Revenue from Revuforj, Niktimvo (Insider Monkey)
Aug-14-25 09:55AM	Does Syndax (SNDX) Have the Potential to Rally 158.36% as Wall Street Analysts Expect? (Zacks) +9.52%
Aug-13-25 01:15AM	FDA Priority Review and Revenue Growth Drive Short-Term Upswing for Syndax Pharmaceuticals (Insider Monkey)
Aug-06-25 04:01PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
11:05AM	Citi ups Syndax target, opens upside catalyst watch (TipRanks)
Aug-04-25 05:15PM	Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Beats Revenue Estimates (Zacks) +21.10%
04:11PM	Syndax: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Syndax Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Jul-29-25 12:00PM	All You Need to Know About Syndax (SNDX) Rating Upgrade to Buy (Zacks) +8.15%
10:00AM	Loading…
10:00AM	Earnings Preview: Jazz Pharmaceuticals (JAZZ) Q2 Earnings Expected to Decline (Zacks)
09:55AM	Wall Street Analysts Predict a 237.83% Upside in Syndax (SNDX): Here's What You Should Know (Zacks)
Jul-28-25 07:00AM	Syndax to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 4, 2025 (GlobeNewswire)
Jul-09-25 12:55AM	Syndax's Revuforj Granted FDA Priority Review for Relapsed/Refractory Mutant NPM1 AML (Insider Monkey) +5.60%
Jul-02-25 04:01PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-24-25 04:01PM	Syndax Announces FDA Priority Review of sNDA for Revuforj (revumenib) in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia (GlobeNewswire)
12:45PM	Syndax Pharmaceuticals Publishes Positive Revumenib Data from BEAT AML Trial (Insider Monkey)
Jun-13-25 12:10PM	Syndax reports publication of revumenib data from BEAT AML trial (TipRanks)
Jun-12-25 12:02PM	Syndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of Clinical Oncology and Simultaneous Presentation at EHA 2025 (GlobeNewswire)
07:00AM	Syndax Presents New Revuforj (revumenib) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 2025 (GlobeNewswire)
Jun-05-25 04:01PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
May-29-25 07:00AM	Syndax Announces Participation in June Investor Conferences (GlobeNewswire)
May-14-25 09:30AM	Syndax Announces Data Presentations at EHA 2025 Showcasing Revuforj (revumenib) and Niktimvo (axatilimab-csfr) (GlobeNewswire) -8.93%
May-12-25 04:01PM	Syndax Pharmaceuticals Appoints Dr. Nicholas Botwood as Head of Research and Development and Chief Medical Officer (GlobeNewswire) -7.28%
May-09-25 09:55AM	Wall Street Analysts See a 219.98% Upside in Syndax (SNDX): Can the Stock Really Move This High? (Zacks)
07:00AM	Loading…
May-08-25 07:00AM	Syndax Announces Participation in May Investor Conferences (GlobeNewswire) +10.21%
May-07-25 04:01PM	Syndax Announces Publication of Pivotal Revumenib Data in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia in the Journal Blood (GlobeNewswire) -6.11%
May-06-25 01:13PM	Q1 2025 Syndax Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -21.59%
03:06AM	Syndax Pharmaceuticals Inc (SNDX) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
May-05-25 05:10PM	Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:08PM	Syndax: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Syndax Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
May-02-25 04:05PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
09:26AM	Syndax Pharmaceuticals Inc (SNDX) Q1 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Apr-28-25 07:00AM	Syndax to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 5, 2025 (GlobeNewswire)
Apr-07-25 09:08AM	Syndax Pharmaceuticals: Down But Not Out (Seeking Alpha)
Apr-04-25 04:05PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) -9.71%
Apr-02-25 07:00AM	Syndax Announces Participation at the Stifel 2025 Virtual Targeted Oncology Forum (GlobeNewswire) +7.99%
Mar-30-25 03:50AM	abrdn Life Sciences Investors Q4 2024 Commentary (Seeking Alpha)
Mar-20-25 01:03PM	3 Promising Biotechs Trading Substantially Under Consensus Analyst Firm Price Targets (SeekingAlpha) +7.47%
Mar-05-25 04:05PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
10:00AM	Syndax Pharmaceuticals Inc (SNDX) Q4 2024 Earnings Call Highlights: Strong Product Launch and ... (GuruFocus.com)
Mar-03-25 08:15AM	Syndax Pharmaceuticals (SNDX) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:13AM	Syndax: Q4 Earnings Snapshot (Associated Press Finance)
07:01AM	Syndax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
Feb-28-25 07:07AM	Earnings To Watch: Syndax Pharmaceuticals Inc (SNDX) Reports Q4 2024 Result (GuruFocus.com)
Feb-25-25 07:00AM	Syndax Announces Participation in March Investor Conferences (GlobeNewswire)
Feb-24-25 07:00AM	Syndax to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call and Webcast on March 3, 2025 (GlobeNewswire)
Feb-04-25 04:05PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Jan-30-25 07:00AM	Syndax Announces Participation in February Investor Conferences (PR Newswire)
Jan-15-25 05:34PM	Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo (axatilimab-csfr) 9 mg and 22 mg Vial Sizes (PR Newswire)
Jan-13-25 07:00AM	Syndax Highlights Recent Accomplishments and Anticipated 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Jan-07-25 07:00AM	Syndax Announces Presentation at 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Jan-03-25 04:05PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Dec-09-24 07:30AM	Syndax Announces Additional Positive Data for Revuforj (revumenib) from AUGMENT-101 Trial in Relapsed or Refractory mNPM1 AML and BEAT AML Frontline Combination Trial (PR Newswire) -8.52%
Dec-07-24 06:15PM	Syndax Presents Positive Revuforj (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting (PR Newswire)
Dec-04-24 01:32PM	Why Is Syndax Pharmaceuticals, Inc. (SNDX) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds? (Insider Monkey)
Dec-03-24 04:05PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Nov-27-24 07:00AM	Syndax Announces Participation at the Citi 2024 Global Healthcare Conference (PR Newswire)
Nov-18-24 07:12AM	Syndax secures FDA OK for new kind of leukemia drug (BioPharma Dive)
06:39AM	FDA approves Syndaxs Revuforj to treat leukaemia (Pharmaceutical Technology)
Nov-15-24 05:29PM	Syndax Announces FDA Approval of Revuforj (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation (PR Newswire) -5.72%
Nov-14-24 08:00AM	Biotech Companies' Q3 Updates: Promising Cancer Treatments on the Horizon (PR Newswire)
Nov-13-24 01:06PM	Syndaxs stock sinks by 25% despite AML trial meeting primary endpoint (Pharmaceutical Technology)
07:21AM	Syndaxs revumenib meets primary results in AML trial (TipRanks)
Nov-12-24 01:07PM	Syndax Pharmaceuticals Stock Falls After Data From Mid-Stage Study Of Revumenib In Form Of Blood Cancer (Benzinga) -25.57%
07:00AM	Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of Revumenib (PR Newswire)
Nov-07-24 12:32AM	Q3 2024 Royalty Pharma PLC Earnings Call (Thomson Reuters StreetEvents)
Nov-06-24 12:16PM	Q3 2024 Syndax Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) +8.43%
05:00AM	Moderna said to shuffle sales leadership; Vertex records first Casgevy sale (BioPharma Dive)
02:23AM	Syndax Pharmaceuticals Inc (SNDX) Q3 2024 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
Nov-05-24 05:10PM	Syndax Pharmaceuticals (SNDX) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:09PM	Syndax: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Syndax Reports Third Quarter 2024 Financial Results and Provides Business Update (PR Newswire)
09:01AM	Syndax to Host ASH Investor Event in Person and via Webcast on December 9, 2024 (PR Newswire)
09:00AM	Syndax Announces Revumenib Abstracts to Be Presented at the 66th ASH Annual Meeting (PR Newswire)
09:00AM	Syndax Announces New Data from Secondary Analysis of the Pivotal AGAVE-201 Trial of Niktimvo (axatilimab-csfr) in Chronic Graft-Versus-Host Disease to Be Presented at 66th ASH Annual Meeting (PR Newswire)
04:32AM	Syndax agrees funding with Royalty Pharma for Niktimvo US sales (Pharmaceutical Technology)
Nov-04-24 04:15PM	Royalty Pharma and Syndax Pharmaceuticals Enter Into $350 Million Royalty Funding Agreement for Niktimvo (GlobeNewswire)
04:01PM	Syndax Pharmaceuticals and Royalty Pharma Enter into $350 Million Royalty Funding Agreement for Niktimvo (PR Newswire)
Nov-01-24 04:05PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
07:00AM	Syndax Announces Participation in November Investor Conferences (PR Newswire)
Oct-29-24 07:00AM	Syndax to Announce Third Quarter 2024 Financial Results and Host Conference Call and Webcast on November 5, 2024 (PR Newswire)
Oct-18-24 03:03PM	State Street Corp's Strategic Acquisition in Syndax Pharmaceuticals (GuruFocus.com)
Oct-09-24 03:54PM	Syndax Pharmaceuticals Inc (SNDX) Q2 2024 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
Oct-04-24 04:05PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Sep-18-24 05:15PM	Incyte and Syndax Announce New England Journal of Medicine Publication of Data from Pivotal AGAVE-201 Trial of Niktimvo (axatilimab-csfr) in Chronic Graft-Versus-Host Disease (PR Newswire)
Sep-06-24 04:05PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Sep-05-24 12:01AM	Syndax Pharmaceuticals, Inc. (SNDX): This Small-Cap Healthcare Stock Is A Good Buy Right Now (Insider Monkey)
Sep-02-24 05:22PM	10 Best Small-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Aug-15-24 12:32PM	FDA greenlights Incyte and Syndaxs GvHD drug Niktimvo (Pharmaceutical Technology)
10:11AM	FDA Approves Incyte/Syndax Partnered Drug For Chronic Graft-Versus-Host Disease, A Post-Transplant Complication (Benzinga)
Aug-14-24 05:34PM	Incyte and Syndax Announce U.S. FDA Approval of Niktimvo (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD) (Business Wire)
Aug-12-24 07:00AM	Syndax Announces Publication in the Journal of Clinical Oncology of Data from the Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia (PR Newswire)
Aug-05-24 04:05PM	Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire) -6.56%

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include SyndAccess, Revuforj, Niktimvo, and IncyteCARES. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Metzger Michael A	Chief Executive Officer	Sep 08 '25	Option Exercise	10.90	157,307	1,714,646	455,968	Sep 08 06:45 PM
Metzger Michael A	Chief Executive Officer	Sep 08 '25	Sale	16.41	157,307	2,582,021	298,661	Sep 08 06:45 PM
MICHAEL METZGER	Director	Sep 08 '25	Proposed Sale	17.04	157,307	2,680,511		Sep 08 04:25 PM
Podlesak Dennis	Director	Aug 14 '25	Option Exercise	7.20	19,200	138,240	210,963	Aug 18 05:02 PM
Podlesak Dennis	Director	Aug 15 '25	Option Exercise	7.20	19,200	138,240	210,963	Aug 18 05:02 PM
Podlesak Dennis	Director	Aug 18 '25	Option Exercise	7.20	19,200	138,240	210,963	Aug 18 05:02 PM
Podlesak Dennis	Director	Aug 18 '25	Sale	15.84	19,200	304,170	191,763	Aug 18 05:02 PM
Podlesak Dennis	Director	Aug 15 '25	Sale	15.54	19,200	298,408	191,763	Aug 18 05:02 PM
Podlesak Dennis	Director	Aug 14 '25	Sale	14.19	19,200	272,521	191,763	Aug 18 05:02 PM
DENNIS G PODLESAK	Director	Aug 18 '25	Proposed Sale	15.74	14,400	226,656		Aug 18 04:36 PM
DENNIS G PODLESAK	Director	Aug 14 '25	Proposed Sale	13.45	43,200	581,040		Aug 14 04:26 PM
Goldan Keith A.	Chief Financial Officer	Jul 16 '25	Sale	9.29	1,296	12,033	92,450	Jul 18 04:30 PM
Metzger Michael A	Chief Executive Officer	Jul 16 '25	Sale	9.29	7,534	69,953	298,661	Jul 18 04:30 PM
Goldan Keith A.	Officer	Jul 16 '25	Proposed Sale	9.29	1,296	12,034		Jul 16 03:29 PM
Metzger Michael A	Officer	Jul 16 '25	Proposed Sale	9.29	7,534	69,955		Jul 16 03:21 PM
Gallagher Neil	Officer	Jul 10 '25	Proposed Sale	9.26	9,679	89,667		Jul 10 03:42 PM
Botwood Nicholas A.J.	Head of R&D, CMO	May 16 '25	Buy	8.99	11,765	105,826	35,165	May 19 04:03 PM
Huber Martin H. Jr.	Director	May 19 '25	Buy	8.99	5,000	44,950	79,000	May 19 04:02 PM
Katkin Keith	Director	May 19 '25	Buy	9.11	10,000	91,120	100,000	May 19 04:01 PM
Metzger Michael A	Chief Executive Officer	Mar 14 '25	Option Exercise	7.20	6,074	43,733	306,195	Mar 17 06:01 AM
Metzger Michael A	Chief Executive Officer	Mar 04 '25	Option Exercise	7.20	7,814	56,261	307,935	Mar 06 04:10 PM
Metzger Michael A	Chief Executive Officer	Mar 04 '25	Sale	15.05	7,814	117,564	300,121	Mar 06 04:10 PM
MICHAEL METZGER	Officer	Mar 04 '25	Proposed Sale	15.48	13,888	214,986		Mar 04 05:10 PM
Goldan Keith A.	Chief Financial Officer	Feb 10 '25	Sale	15.50	3,777	58,559	90,746	Feb 12 05:16 PM
Metzger Michael A	Chief Executive Officer	Feb 10 '25	Sale	15.50	13,288	206,017	300,121	Feb 12 05:15 PM
Gallagher Neil	President, Head of R&D	Feb 10 '25	Sale	15.50	4,618	71,597	85,095	Feb 12 05:13 PM
Goldan Keith A.	Officer	Feb 10 '25	Proposed Sale	15.50	3,777	58,559		Feb 10 03:29 PM
Metzger Michael A	Officer	Feb 10 '25	Proposed Sale	15.50	13,288	206,017		Feb 10 03:20 PM
Gallagher Neil	Officer	Feb 10 '25	Proposed Sale	15.50	4,618	71,597		Feb 10 03:17 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SNDX

Syndax Pharmaceuticals Inc

Upgrade your FINVIZ experience